Background and Objectives: Highly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca‐gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin‐inhibitor, low‐cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca‐gluconate.Materials and Methods: Eight blood centres determined PG weight and volume of non‐gelled, liquid portion in 116 PG prepared in 20‐mL commercial BioNest D bags. Ten‐millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca‐gluconate and 0.4 mL of TXA. After 30‐min incubation, PG weight and non‐gelled liquid volume were determined.Results: PG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.Conclusion: This study provides preliminary evidence supporting the use of TXA as a low‐cost reagent for PG manufacturing from platelets in 100% plasma.